News | October 18, 2010

Italian Man Surpasses 1,000 Days Of Support With Artificial Heart

October 18, 2010 - A 54-year-old Italian man has become the first patient to surpass 1,000 days of support with an artificial heart while waiting for a matching donor heart. The patient was implanted with the SynCardia temporary Total Artificial Heart.

“Life is a wonderful present that has to be respected,” said patient Pietro Zorzetto. “The Total Artificial Heart allowed me to recover to a very healthy physical condition. I really want to thank the SynCardia Total Artificial Heart for these unexpected 1,000 days of life.”

Zorzetto was first admitted to Azienda Ospedaliera di Padova on Nov. 30, 2007, suffering from valvular cardiomyopathy. Two previous operations at a different hospital had failed to repair his failing heart. Less than a week later, Zorzetto made history when he became the first patient in Italy to be implanted with the SynCardia Total Artificial Heart.

“The Total Artificial Heart provides excellent cardiac output, which restored our patient to normal condition despite the fact he presented with severe multi-organ failure,” said professor Gino Gerosa. “The Total Artificial Heart in combination with the portable driver has been extremely effective in providing the patient with a good quality of life with excellent exercise capacity.”

Zorzetto has been at home since Feb. 4, 2008, when he was discharged from the hospital using a portable driver to power his artificial heart. On a typical day, he walks 10 km and then exercises for an additional 30 minutes in his gym at home to stay in shape for a transplant.

For more information: www.syncardia.com

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...